$Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia$

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/...

Full description

Bibliographic Details
Main Authors:	Stein, EM, DiNardo, CD, Pollyea, DA, Fathi, AT, Roboz, GJ, Altman, JK, Stone, RM, DeAngelo, DJ, Levine, RL, Flinn, IW, Kantarjian, HM, Collins, R, Patel, MR, Frankel, AE, Stein, A, Sekeres, MA, Swords, RT, Medeiros, BC, Willekens, C, Vyas, P, Tosolini, A, Xu, Q, Knight, RD, Yen, KE, Agresta, S, De Botton, S, Tallman, MS
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2017

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Similar Items